Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes

Table 5 Multivariate logistic regression analysis for the association between mt12361A>G and metabolic dysfunction-associated steatotic liver disease among the non-diabetic subgroup, mean ± SD/n (%)

	Univariate			Multivariate
	MASLD	Control	P value	OR	95%CI	P value
n (%)	508 (42.5)	687 (57.5)
Age (years)	49.1 ± 11.9	47.0 ± 13.7	0.005	1.02	1.01-1.03	0.002
Sex (male)	293 (57.8)	256 (37.4)	2.7 × 10-12	1.47	1.12-1.93	0.005
Cholesterol (mg/dL)	199.7 ± 37.6	193.5 ± 37.7	0.005	0.99	0.98-1.00	5.7 × 10-4
LDL (mg/dL)	133.3 ± 35.6	120.2 ± 33.9	2.0 × 10-10	1.02	1.01-1.02	2.3 × 10-7
AST ULN ratio	0.61 ± 0.28	0.55 ± 0.30	4.3 × 10-4	0.17	0.06-0.48	0.001
ALT ULN ratio	0.69 ± 0.46	0.49 ± 0.35	9.4 × 10-16	10.77	5.34-21.71	3.2 × 10-11
mt12361A>G	22 (4.6)	11 (1.7)	0.004	2.80	1.22-6.41	0.015

OR: Odds ratio; CI: Confidence interval; MASLD: Metabolic dysfunction-associated steatotic liver disease; LDL: Low density lipoprotein cholesterol; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ULN: Upper limit of normal.